TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors

Histone deacetylases (HDACs) have been implicated in multiple malignant tumors, and HDAC inhibitors (HDACIs) exert anti-cancer effects. However, the expression of HDACs and the anti-tumor mechanism of HDACIs in cholangiocarcinoma (CCA) have not yet been elucidated. In this study, we found that expre...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Jun-chuang, Yao, Wei, Wang, Jian-ming, Schemmer, Peter, Yang, Yan, Liu, Yan, Qian, Ya-wei, Qi, Wei-peng, Zhang, Jian, Shen, Qi, Yang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342751/
https://www.ncbi.nlm.nih.gov/pubmed/27705912
http://dx.doi.org/10.18632/oncotarget.12254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342751/
https://www.ncbi.nlm.nih.gov/pubmed/27705912
http://dx.doi.org/10.18632/oncotarget.12254

Ejemplares similares